Cargando…
Could tau-PET imaging contribute to a better understanding of the different patterns of clinical progression in Alzheimer’s disease? A 2-year longitudinal study
BACKGROUND: Monitoring the progression of Tau pathology makes it possible to study the clinical diversity of Alzheimer’s disease. In this 2-year longitudinal PET study, we aimed to determine the progression of [(18)F]-flortaucipir binding and of cortical atrophy, and their relationships with cogniti...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155356/ https://www.ncbi.nlm.nih.gov/pubmed/37138309 http://dx.doi.org/10.1186/s13195-023-01237-2 |
_version_ | 1785036311611047936 |
---|---|
author | Lagarde, Julien Olivieri, Pauline Tonietto, Matteo Rodrigo, Sébastian Gervais, Philippe Caillé, Fabien Moussion, Martin Bottlaender, Michel Sarazin, Marie |
author_facet | Lagarde, Julien Olivieri, Pauline Tonietto, Matteo Rodrigo, Sébastian Gervais, Philippe Caillé, Fabien Moussion, Martin Bottlaender, Michel Sarazin, Marie |
author_sort | Lagarde, Julien |
collection | PubMed |
description | BACKGROUND: Monitoring the progression of Tau pathology makes it possible to study the clinical diversity of Alzheimer’s disease. In this 2-year longitudinal PET study, we aimed to determine the progression of [(18)F]-flortaucipir binding and of cortical atrophy, and their relationships with cognitive decline. METHODS: Twenty-seven AD patients at the mild cognitive impairment/mild dementia stages and twelve amyloid-negative controls underwent a neuropsychological assessment, 3 T brain MRI, and [(18)F]-flortaucipir PET imaging (Tau1) and were monitored annually over 2 years with a second brain MRI and tau-PET imaging after 2 years (Tau2). We analyzed the progression of tau standardized uptake value ratio (SUVr) and grey matter atrophy both at the regional and voxelwise levels. We used mixed effects models to explore the relations between the progression of SUVr values, cortical atrophy, and cognitive decline. RESULTS: We found an average longitudinal increase in tau SUVr values, except for the lateral temporoparietal cortex where the average SUVr values decreased. Individual analyses revealed distinct profiles of SUVr progression according to temporoparietal Tau1 uptake: high-Tau1 patients demonstrated an increase in SUVr values over time in the frontal lobe, but a decrease in the temporoparietal cortex and a rapid clinical decline, while low-Tau1 patients displayed an increase in SUVr values in all cortical regions and a slower clinical decline. Cognitive decline was strongly associated with the progression of regional cortical atrophy, but only weakly associated with SUVr progression. CONCLUSIONS: Despite a relatively small sample size, our results suggest that tau-PET imaging could identify patients with a potentially “more aggressive” clinical course characterized by high temporoparietal Tau1 SUVr values and a rapid clinical progression. In these patients, the paradoxical decrease in temporoparietal SUVr values over time could be due to the rapid transition to ghost tangles, for which the affinity of the radiotracer is lower. They could particularly benefit from future therapeutic trials, the neuroimaging outcome measures of which deserve to be discussed. |
format | Online Article Text |
id | pubmed-10155356 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-101553562023-05-04 Could tau-PET imaging contribute to a better understanding of the different patterns of clinical progression in Alzheimer’s disease? A 2-year longitudinal study Lagarde, Julien Olivieri, Pauline Tonietto, Matteo Rodrigo, Sébastian Gervais, Philippe Caillé, Fabien Moussion, Martin Bottlaender, Michel Sarazin, Marie Alzheimers Res Ther Research BACKGROUND: Monitoring the progression of Tau pathology makes it possible to study the clinical diversity of Alzheimer’s disease. In this 2-year longitudinal PET study, we aimed to determine the progression of [(18)F]-flortaucipir binding and of cortical atrophy, and their relationships with cognitive decline. METHODS: Twenty-seven AD patients at the mild cognitive impairment/mild dementia stages and twelve amyloid-negative controls underwent a neuropsychological assessment, 3 T brain MRI, and [(18)F]-flortaucipir PET imaging (Tau1) and were monitored annually over 2 years with a second brain MRI and tau-PET imaging after 2 years (Tau2). We analyzed the progression of tau standardized uptake value ratio (SUVr) and grey matter atrophy both at the regional and voxelwise levels. We used mixed effects models to explore the relations between the progression of SUVr values, cortical atrophy, and cognitive decline. RESULTS: We found an average longitudinal increase in tau SUVr values, except for the lateral temporoparietal cortex where the average SUVr values decreased. Individual analyses revealed distinct profiles of SUVr progression according to temporoparietal Tau1 uptake: high-Tau1 patients demonstrated an increase in SUVr values over time in the frontal lobe, but a decrease in the temporoparietal cortex and a rapid clinical decline, while low-Tau1 patients displayed an increase in SUVr values in all cortical regions and a slower clinical decline. Cognitive decline was strongly associated with the progression of regional cortical atrophy, but only weakly associated with SUVr progression. CONCLUSIONS: Despite a relatively small sample size, our results suggest that tau-PET imaging could identify patients with a potentially “more aggressive” clinical course characterized by high temporoparietal Tau1 SUVr values and a rapid clinical progression. In these patients, the paradoxical decrease in temporoparietal SUVr values over time could be due to the rapid transition to ghost tangles, for which the affinity of the radiotracer is lower. They could particularly benefit from future therapeutic trials, the neuroimaging outcome measures of which deserve to be discussed. BioMed Central 2023-05-03 /pmc/articles/PMC10155356/ /pubmed/37138309 http://dx.doi.org/10.1186/s13195-023-01237-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Lagarde, Julien Olivieri, Pauline Tonietto, Matteo Rodrigo, Sébastian Gervais, Philippe Caillé, Fabien Moussion, Martin Bottlaender, Michel Sarazin, Marie Could tau-PET imaging contribute to a better understanding of the different patterns of clinical progression in Alzheimer’s disease? A 2-year longitudinal study |
title | Could tau-PET imaging contribute to a better understanding of the different patterns of clinical progression in Alzheimer’s disease? A 2-year longitudinal study |
title_full | Could tau-PET imaging contribute to a better understanding of the different patterns of clinical progression in Alzheimer’s disease? A 2-year longitudinal study |
title_fullStr | Could tau-PET imaging contribute to a better understanding of the different patterns of clinical progression in Alzheimer’s disease? A 2-year longitudinal study |
title_full_unstemmed | Could tau-PET imaging contribute to a better understanding of the different patterns of clinical progression in Alzheimer’s disease? A 2-year longitudinal study |
title_short | Could tau-PET imaging contribute to a better understanding of the different patterns of clinical progression in Alzheimer’s disease? A 2-year longitudinal study |
title_sort | could tau-pet imaging contribute to a better understanding of the different patterns of clinical progression in alzheimer’s disease? a 2-year longitudinal study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155356/ https://www.ncbi.nlm.nih.gov/pubmed/37138309 http://dx.doi.org/10.1186/s13195-023-01237-2 |
work_keys_str_mv | AT lagardejulien couldtaupetimagingcontributetoabetterunderstandingofthedifferentpatternsofclinicalprogressioninalzheimersdiseasea2yearlongitudinalstudy AT olivieripauline couldtaupetimagingcontributetoabetterunderstandingofthedifferentpatternsofclinicalprogressioninalzheimersdiseasea2yearlongitudinalstudy AT toniettomatteo couldtaupetimagingcontributetoabetterunderstandingofthedifferentpatternsofclinicalprogressioninalzheimersdiseasea2yearlongitudinalstudy AT rodrigosebastian couldtaupetimagingcontributetoabetterunderstandingofthedifferentpatternsofclinicalprogressioninalzheimersdiseasea2yearlongitudinalstudy AT gervaisphilippe couldtaupetimagingcontributetoabetterunderstandingofthedifferentpatternsofclinicalprogressioninalzheimersdiseasea2yearlongitudinalstudy AT caillefabien couldtaupetimagingcontributetoabetterunderstandingofthedifferentpatternsofclinicalprogressioninalzheimersdiseasea2yearlongitudinalstudy AT moussionmartin couldtaupetimagingcontributetoabetterunderstandingofthedifferentpatternsofclinicalprogressioninalzheimersdiseasea2yearlongitudinalstudy AT bottlaendermichel couldtaupetimagingcontributetoabetterunderstandingofthedifferentpatternsofclinicalprogressioninalzheimersdiseasea2yearlongitudinalstudy AT sarazinmarie couldtaupetimagingcontributetoabetterunderstandingofthedifferentpatternsofclinicalprogressioninalzheimersdiseasea2yearlongitudinalstudy |